IPOMarket.in — India IPO tracker
Ch 7/10
Back to Grey Market Premium — The Insider's Guide
6 min read1,028 words

When GMP Lies — Famous Prediction Failures

History is the best teacher in financial markets. This chapter examines specific IPO episodes where GMP was significantly wrong — where high GMP preceded either a flat listing or an outright listing loss. For each case, we identify the warning signs that were visible before listing.

The goal is not to discredit GMP as a tool — it remains useful. The goal is to build your ability to recognise when GMP is unreliable, so you are not blindsided.

Case Study 1: The Large Technology IPO Disappointment (Paytm, 2021)

The pre-listing picture: One 97 Communications (Paytm) raised ₹18,300 crore in November 2021 — at the time, the largest IPO in Indian history. GMP was positive heading into listing. The IPO was subscribed 1.89x overall, with QIB subscription at 2.79x.

What happened at listing: Paytm listed at ₹1,560 — a 27% discount to its issue price of ₹2,150. It continued falling, eventually losing over 70% from the issue price.

The warning signs that GMP ignored:

  1. QIB subscription was only 2.79x — for an ₹18,300 crore issue, this was a signal of limited institutional enthusiasm. GMP remained positive despite this signal.

  2. Valuation was extreme: Paytm was priced at a market cap of approximately $20 billion with negative operating cash flow and no clear near-term profitability path. The "Basis of Issue Price" used comparables that stretched the definition of "comparable."

  3. Large OFS component: A significant portion of the IPO was selling shareholders — early investors and SoftBank — exiting. These sellers had committed to selling into any listing-day demand.

  4. The GMP was driven by retail sentiment, not institutional conviction: The relatively weak QIB subscription vs the positive GMP was a divergence that, in hindsight, clearly signalled that institutional and retail sentiment were misaligned.

The lesson: GMP reflected retail FOMO in a hot IPO market. QIB subscription gave the more honest signal. When QIB and GMP diverge significantly, prioritise QIB.

Case Study 2: The Utilities Giant (LIC, 2022)

The pre-listing picture: Life Insurance Corporation of India raised ₹20,557 crore in May 2022. The IPO was well received — subscribed approximately 3x overall. GMP for retail investors (applying at the standard price) was in positive territory before listing.

What happened at listing: LIC listed at ₹872 against an issue price of ₹949 for retail investors — an 8% listing loss. The stock continued declining in the weeks following listing.

The warning signs that GMP ignored:

  1. Market conditions deteriorated sharply between IPO close and listing: The Russian invasion of Ukraine, aggressive US Federal Reserve rate hikes, and global equity market selloff created a fundamentally different market environment on listing day than when the GMP was set.

  2. The issue size was enormous — creating significant selling supply: ₹20,557 crore in shares entering the market simultaneously created a supply-demand imbalance that no amount of retail buying could absorb, especially in a weak market.

  3. Domestic institutional investors (DIIs) had absorbed most QIB allocation: FII participation was limited. In a market downturn, FII selling pressure at listing was not matched by domestic buying.

  4. The valuation left limited upside: At the issue price, LIC was not expensive by Indian insurance standards, but it was not cheap enough to create aggressive post-listing buying demand from value investors.

The lesson: For very large IPOs, assess the macroeconomic and market conditions as carefully as the company fundamentals. GMP cannot account for market regime changes between subscription close and listing. For LIC-scale issues, even small shifts in institutional risk appetite create listing price pressure that dwarfs grey market predictions.

Case Study 3: The Overvalued SME Technology Issue

The archetype: A niche technology company lists on NSE Emerge. GMP builds to 40–50% above issue price during the subscription period. The IPO is subscribed 80x. Social media is full of excitement. Retail investors are applying in large numbers.

What happened: Listed at 20% premium (below GMP prediction). Continued declining for 3 months after listing, eventually trading below issue price.

The warning signs that GMP ignored:

  1. No QIB participation: SME IPOs often have no QIBs — no institutional backstop. The 80x subscription and 40–50% GMP were entirely retail/HNI driven, subject to FOMO dynamics without institutional discipline.

  2. Valuation at issue price was aggressive: The company was priced at 35x P/E in a sector where listed peers traded at 20x. No specific differentiator justified the premium.

  3. OFS dominated: 75% of the issue was OFS by promoters. The promoter reduced from 72% to 30% stake.

  4. GMP was operator-driven: The grey market premium was significantly inflated by coordinated dealer activity — buying up applications to create the appearance of demand and drive retail subscription higher.

The lesson: In SME IPOs, the absence of QIB participation means GMP is entirely driven by retail sentiment and potentially operator activity. Without institutional cross-check, SME GMP reliability drops significantly. Combine with fundamental analysis.

The Pattern Across All Failures

The warning signs that consistently preceded GMP prediction failures:

  1. QIB subscription tepid or absent while GMP was high
  2. Large OFS component creating selling supply at listing
  3. Market conditions deteriorating between IPO close and listing
  4. Extreme GMP (40%+) suggesting speculative froth rather than value demand
  5. Aggressive valuation at issue price with limited room for positive re-rating
  6. Operator activity suspected (SME IPOs with no institutional participation and very high GMP)

Building a checklist of these warning signs and checking it before treating GMP as reliable will substantially reduce listing-day surprises.